A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas.

Authors

null

Michael J. Overman

University of Texas MD Anderson Cancer Center, Houston, TX;

Michael J. Overman , Ramzi Melhem , Mariela A. Blum-Murphy , Claudia Ramos , Lina Petrosyan , Jack Li , Jessica K Perer , Hui Zou , Ming Wang , Harold M Wright

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05482893

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS765)

DOI

10.1200/JCO.2023.41.4_suppl.TPS765

Abstract #

TPS765

Poster Bd #

Q1

Abstract Disclosures

Similar Posters

First Author: Hui Kong Gan

First Author: Soohyeon Lee

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.

First Author: Jing Huang